Like the company said a news is coming from FDA With FDA 510K clearance, as well as CMS underwriting and the new HCPCS Level II designation code recommendations and review process complete, the company expects permanent code approval for Venowave to be imminent,” said Rob Fia, CEO of Therma Bright. “Our distribution partners are ready to begin their work to deploy our Venowave in their network of Medicare and Medicaid medical practitioners to help their patients with a variety of circulatory conditions, including deep vein thrombosis (DVT) and pulmonary embolism (PE), which, according to the Centers for Disease Control and Prevention (CDC), affect more than 900,000 U.S. citizens each year.”
So Be IN before